Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T.
Mori K, et al. Among authors: ueda k.
Cancer Sci. 2024 Nov 17. doi: 10.1111/cas.16326. Online ahead of print.
Cancer Sci. 2024.
PMID: 39550694
Free article.